A strong clinical discovery can lose its path to translation if intellectual property is not considered early enough. Knowing when, why and how to protect an idea is often the difference between a research project that stays in the lab and one that reaches patients.

Featuring Prof Victoria Cogger (CEO, Sydney Biomedical Accelerator), Michael Powell (Commercialisation Manager, WSLHD), Adam Wardell (Industry Growth Program Advisor) and Sylvie Tso (Partner, Spruson & Ferguson), Cicada Innovations is delivering this session with Kids Research/SCHN for clinicians, researchers and health innovators working on translational projects and emerging health technologies who want a clearer view of how IP protection fits into the work.

It covers the practical questions: when protection matters, why it matters, and how to approach it in a clinical research setting. Registration is open to all interested attendees.

By the end of the masterclass, you’ll know:

• When and why to consider IP protection across clinical research, translational projects and emerging health technologies
• How clinicians and researchers can approach IP decisions in practice
• The answers to your live questions during the Q&A

Who it’s for: Clinicians, researchers, allied health staff and hospital staff looking to commercialise their research from the public hospital system.